GlassScriptPhysician profile
Whitney Lynn Phillips
NPI 1497111579
$9,409.68
in general payments reported to CMS, 2019-2025
31 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,416 · 2022: $2,582 · 2023: $2,779 · 2024: $1,508 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,332 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,331.87 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,825.32 | 2021-2024 | |
| Amgen INC. | $1,046.46 | 2021-2024 | Tavneos, Enbrel, Krystexxa |
| Ucb, INC. | $926.18 | 2021-2024 | Cimzia |
| Janssen Biotech, INC. | $714.68 | 2021-2024 | Tremfya, Remicade, Stelara |
| Ani Pharmaceuticals, INC. | $637.57 | 2022-2024 | Purified Cortrophin Gel |
| Novartis Pharmaceuticals Corporation | $451.17 | 2021-2024 | |
| Mallinckrodt Hospital Products INC. | $390.96 | 2021-2024 | Acthar |
| Lilly USA, LLC | $379.70 | 2021-2024 | Taltz |
| Aurinia Pharma U.S., INC. | $378.59 | 2022-2024 | Lupkynis |
| Actelion Pharmaceuticals US, INC. | $367.83 | 2021-2024 | Uptravi, Opsumit |
| Fresenius Kabi USA, LLC | $359.63 | 2023-2024 | Idacio |
| Astrazeneca Pharmaceuticals LP | $338.65 | 2021-2024 | Saphnelo |
| Sobi, INC | $251.52 | 2021-2025 | |
| Pfizer INC. | $245.96 | 2021-2024 | |
| Organon LLC | $158.04 | 2021-2024 | Hadlima, Renflexis |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $144.06 | 2021-2024 | Actemra |
| Radius Health, INC. | $132.91 | 2021-2024 | Tymlos |
| Glaxosmithkline, LLC. | $98.05 | 2021-2024 | Benlysta, Nucala |
| Alexion Pharmaceuticals, INC. | $85.81 | 2021-2023 | Strensiq |
| E.R. Squibb & Sons, L.L.C. | $77.05 | 2021-2023 | Orencia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.26 | 2022-2024 | Cyltezo |
| Horizon Therapeutics Plc | $63.33 | 2021-2022 | |
| Sandoz INC. | $53.89 | 2023 | Hyrimoz |
| Ultragenyx Pharmaceutical INC. | $49.16 | 2022 | |
| Merck Sharp & Dohme LLC | $41.23 | 2023-2024 | Winrevair |
| Currax Pharmaceuticals LLC | $29.64 | 2021 | |
| Novo Nordisk INC | $27.58 | 2023-2024 | Wegovy |
| Daiichi Sankyo INC. | $23.59 | 2021 | |
| Genzyme Corporation | $18.52 | 2021 | |
| Octapharma USA, INC. | $14.37 | 2022 | |
| Medexus Pharma, INC. | $11.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Whitney Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.